

260-7118; or via E-mail at: fields.wanda@epa.gov.

Anyone wishing to make an oral presentation at the meeting must contact Ms. Roslyn Edson, Designated Federal Officer, *in writing*, no later than 5 p.m. noon Eastern Time on January 15, 1999, by fax (202) 260-7118, or via E-mail: edson.roslyn@epa.gov. The request should identify the name of the individual who will make the presentation and an outline of the issues to be addressed. At least 35 copies of any written comments to the Committee are to be given to Ms. Edson no later than the time of the presentation for distribution to the Committee and the interested public.

Providing Oral or Written Comments at SAB Meetings

The Science Advisory Board expects that public statements presented at its meetings will not be repetitive of previously submitted oral or written statements. In general, each individual or group making an oral presentation will be limited to a total time of ten minutes. For conference call meetings, opportunities for oral comment will be limited to no more than five minutes per speaker and no more than fifteen minutes total. Written comments (at least 35 copies) received in the SAB Staff Office sufficiently prior to the meeting date, may be mailed to the Subcommittee prior to its meeting; comments received too close to the meeting date will normally be provided to the Subcommittee at its meeting. Written comments may be provided to the Subcommittee up until the time of the meeting.

Information concerning the Science Advisory Board, its structure, function, and composition, may be found in The FY1998 Annual Report of the Staff Director which is available from the SAB Committee Evaluation and Support Staff (CESS) by contacting US EPA, Science Advisory Board (1400), Attention: CESS, 401 M Street, SW, Washington, DC 20460 or via fax (202) 260-1889. Additional information concerning the SAB can be found on the SAB Home Page at: <http://www.epa.gov/sab>

Meeting Access

Individuals requiring special accommodation at this meeting, including wheelchair access, should contact Ms. Roslyn Edson at 202-260-3823, via fax at 202-260-7118 or via E-mail at edson.roslyn@epa.gov at least five business days prior to the meeting so that appropriate arrangements can be made.

Dated: December 23, 1998.

Donald G. Barnes,

Staff Director, Science Advisory Board.

[FR Doc. 98-34822 Filed 12-31-98; 8:45 am]

BILLING CODE 6560-50-P

FEDERAL COMMUNICATIONS COMMISSION

Notice of Public Information Collection(s) Submitted to OMB for Review and Approval

December 23, 1998.

SUMMARY: The Federal Communications Commission, as part of its continuing effort to reduce paperwork burden invites the general public and other Federal agencies to take this opportunity to comment on the following information collection, as required by the Paperwork Reduction Act of 1995, Public Law 104-13. An agency may not conduct or sponsor a collection of information unless it displays a currently valid control number. No person shall be subject to any penalty for failing to comply with a collection of information subject to the Paperwork Reduction Act (PRA) that does not display a valid control number. Comments are requested concerning (a) whether the proposed collection of information is necessary for the proper performance of the functions of the Commission, including whether the information shall have practical utility; (b) the accuracy of the Commission's burden estimate; (c) ways to enhance the quality, utility, and clarity of the information collected; and (d) ways to minimize the burden of the collection of information on the respondents, including the use of automated collection techniques or other forms of information technology.

DATES: Written comments should be submitted on or before February 3, 1999. If you anticipate that you will be submitting comments, but find it difficult to do so within the period of time allowed by this notice, you should advise the contact listed below as soon as possible.

ADDRESSES: Direct all comments to Les Smith, Federal Communications Commissions, 445 12th Street, S.W., Washington, DC 20554 or via the Internet to lesmith@fcc.gov.

FOR FURTHER INFORMATION CONTACT: For additional information or copies of the information collections contact Les Smith at (202) 418-0217 or via the Internet at lesmith@fcc.gov.

SUPPLEMENTARY INFORMATION:

OMB Control Number: 3060-0433.

Title: Basic Signal Leakage Performance Report.

Form Number: FCC 320.

Type of Review: Extension of a currently approved collection.

Respondents: Businesses or other for-profit entities.

Number of Respondents: 33,000.

Estimated Time per Response: 20 hours.

Frequency of Response: Annually.

Total Annual Burden: 660,000 hours.

Total Annual Costs: \$3,750.

Needs and Uses: Cable television system operators who use frequencies in the bands 108-137 and 225-400 MHz (aeronautical frequencies) are required to file a cumulative signal leakage index (CLI) derived under Section 76.611(a)(1) or the results of airspace measurements derived under Section 76.611(a)(2). This filing must include a description of the method by which compliance with basic signal leakage criteria is achieved and the method of calibrating the measurement equipment. This yearly filing is done in accordance with Section 76.615 with the use of FCC Form 320. The data collected on the FCC Form 320 are used by Commission staff to ensure the safe operation of aeronautical and marine radio services, and to monitor for compliance of cable aeronautical usage in order to minimize future interference to these safety of life services.

Federal Communications Commission.

William F. Caton,

Deputy Secretary.

[FR Doc. 98-34761 Filed 21-31-98; 8:45 am]

BILLING CODE 6712-01-P

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System.

TIME AND DATE: 10:00 a.m., Wednesday, January 6, 1999.

PLACE: Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, N.W., Washington, D.C. 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.

2. Any matters carried forward from a previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION: Lynn S. Fox, Assistant to the Board; 202-452-3204.

SUPPLEMENTARY INFORMATION: You may call 202-452-3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at <http://www.federalreserve.gov> for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: December 30, 1998.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. 98-34825 Filed 12-30-98; 10:32 am]

BILLING CODE 6210-01-P

FEDERAL RETIREMENT THRIFT INVESTMENT BOARD

Sunshine Act Meeting

TIME AND DATE: 10:00 a.m. (EST) January 11, 1999.

PLACE: 4th Floor, Conference Room 4506, 1250 H Street, N.W., Washington, D.C.

STATUS: Open.

MATTERS TO BE CONSIDERED:

1. Approval of the minutes of the December 14, 1998, Board member meeting.
2. Thrift Savings Plan activity report by the Executive Director.

CONTACT PERSON FOR MORE INFORMATION: Thomas J. Trabucco, Director, Office of External Affairs, (202) 942-1640.

Dated: December 30, 1998.

John J. O'Meara,

Secretary to the Board, Federal Retirement Thrift Investment Board.

[FR Doc. 98-34829 Filed 12-30-98; 1:27 pm]

BILLING CODE 6760-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has made a final finding of scientific misconduct in the following case:

Saptarshi Paul, Ph.D., Fox Chase Cancer Center: Based on a report forwarded to the Office of Research Integrity (ORI) by Fox Chase Cancer Center (FCCC), Institute for Cancer Research, dated July 28, 1997, Dr. Paul's admissions, and information obtained

by ORI during its oversight review, ORI found that Dr. Paul, former research associate, Molecular Oncology Division, FCCC, engaged in scientific misconduct in biomedical research funded by a National Cancer Institute (NCI), National Institutes of Health (NIH), grant. This project seeks improvements in cancer treatment through the development of agents that fight cellular resistance to drugs.

Specifically, Dr. Paul falsified an experiment on the uptake of all-trans retinoic acid (ATR) by HL60 cells conducted by several researchers during July 1997. Although this experiment was not published, the discovery of the falsified data led to admissions by Dr. Paul that he had altered an experiment and an acknowledgment that publications would need to be retracted. Several publications were retracted in whole or in part, and portions of two grant applications were retracted.

Dr. Paul has accepted the ORI finding and has entered into a Voluntary Exclusion Agreement with ORI in which he has voluntarily agreed, for the three (3) year period beginning December 18, 1998:

(1) To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government as defined in 45 C.F.R. Part 76 (Debarment Regulations); and

(2) To exclude himself from serving in any advisory capacity to the Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT:

Acting Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443-5330

Chris B. Pascal,

Acting Director, Office of Research Integrity.

[FR Doc. 98-34760 Filed 12-31-98; 8:45 am]

BILLING CODE 4160-17-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Hematology and Pathology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee

of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Hematology and Pathology Devices Panel of the Medical Devices Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on January 19, 1999, 9:30 a.m. to 4 p.m., and January 20, 1999, 9 a.m. to 4:30 p.m.

Location: Holiday Inn, Walker/Whetstone Salons, Two Montgomery Village Ave., Gaithersburg, MD.

Contact Person: Veronica J. Calvin, Center for Devices and Radiological Health (HFZ-440), Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 301-594-1243, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12515. Please call the Information Line for up-to-date information on this meeting.

Agenda: On January 20, 1999, the committee will: (1) Discuss, make recommendations, and vote on a petition for reclassification of automated differential cell counters in Class III and (2) establish a new classification for flow cytometers.

Procedure: On January 20, 1999, from 9 a.m. to 4:30 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by January 6, 1999. Oral presentations from the public will be scheduled between approximately 9:15 a.m. and 9:45 a.m. Near the end of the committee deliberations, a 30-minute open public session will be conducted for interested persons to address issues specific to the submission or topic before the committee. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before January 6, 1999, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations. On January 19, 1999, from 9:30 a.m. to 4 p.m., the meeting will be closed to the public. The committee will hear and review trade secret and/or confidential commercial information on a product